![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Favrille Announces Initiation of Phase II Clinical Trial in Europe
Favrille Announces Initiation of Phase II Clinical Trial in Europe
June 7, 2005
Favrille has announced that the first patient has been enrolled in a physician-sponsored Phase II clinical trial evaluating the company's lead product candidate, FavId.
The European-only trial is being conducted by Franco Cavalli and is open to patients with all subtypes of indolent B-cell non-Hodgkin's lymphoma.
Both treatment-naive patients and patients who are relapsed or refractory to prior treatments for their disease are eligible for the trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct